{
    "2019-03-06": [
        [
            {
                "time": "2019-03-06",
                "original_text": "After Hours Most Active for Mar 6, 2019: GE, LLY, WBA, WRE, BAC, V, SHY, S, SBUX, AAPL, QQQ, PACB",
                "features": {
                    "keywords": [
                        "after hours",
                        "most active",
                        "LLY",
                        "GE"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-06",
                "original_text": "Lilly's Emgality Gets FDA Priority Review for Cluster Headache",
                "features": {
                    "keywords": [
                        "Emgality",
                        "FDA",
                        "priority review",
                        "cluster headache"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-06",
                "original_text": "J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression",
                "features": {
                    "keywords": [
                        "JNJ",
                        "Spravato",
                        "FDA",
                        "depression"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-06",
                "original_text": "3 Big Pharmas Trying to Pop the Rebate Bubble",
                "features": {
                    "keywords": [
                        "big pharmas",
                        "rebate bubble"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-06",
                "original_text": "FDA Approves Major Novel Depression Drug For First Time In 3 Decades",
                "features": {
                    "keywords": [
                        "FDA",
                        "novel drug",
                        "depression",
                        "approval"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-06",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly",
                        "report"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}